Early access
Sign in
Taking people in Hong KongNo phase

Chemotherapy followed by surgery for returning ovarian cancer

Tests chemotherapy followed by surgery in adults with ovarian cancer that has returned.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Status
Recruiting
People taking part
18 people, planned
Started
1 Nov 2023
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Carboplatin or cisplatin
  • Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
  • Bevacizumab or biosimilar
  • Cytoreductive surgery
Record updated
11 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 or older whose epithelial ovarian, fallopian tube or primary peritoneal cancer has come back after platinum-based chemotherapy, and for whom immediate second surgery is not possible.

Age
18 years or older
Sex
Women only
Disease stage
First recurrence of epithelial ovarian, fallopian tube or primary peritoneal cancer that is platinum-sensitive. Immediate second surgery (secondary cytoreduction) must not be possible.
Earlier treatment
At least 3 cycles of platinum-based chemotherapy at first treatment, with or without bevacizumab and/or PARPi. At least 6 months must have passed since the last platinum dose.

Main reasons for not taking part

  • Non-epithelial or borderline tumors
  • Another cancer within the last five years (a few minor types are allowed)
  • More than one line of chemotherapy
  • Platinum-resistant or refractory recurrence
  • Second relapse or later

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
  • >= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
  • Platinum-free interval should be >=6 months from the last dose of platinum-based chemotherapy
  • Upfront SCR not feasible
  • Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment
  • Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment

Who cannot take part

  • Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded
  • Patients using more than one line of chemotherapy are excluded
  • Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment
  • Non-epithelial or borderline tumors are excluded
  • Patients who have platinum-resistant or refractory recurrence are excluded
  • Patients having second relapse or beyond are excluded

Where in Hong Kong

  • The University of Hong KongHong Kong, Hong KongContact: Lesley LauTaking people

About the trial

What the trial wants to find out

About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.

The group in the trial

  • Chemotherapy and surgery armTreatment being tested

    Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.

    Treatment: Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar, and Cytoreductive surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study
Plain-language title
Chemotherapy followed by surgery for returning ovarian cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 June 2025